Видео с ютуба Esr1 Mutation

ER-positive, HER2-positive Disease and ESR1 Mutations: What's Next?

Elacestrant - Not Just for ESR1 Mutations

Patients Voice - Exploring the Role of ESR1 Testing & Liquid Biopsy in Metastatic Breast Cancer Care

Patients Progressing on an AI ± CDK4/6 Inhibitors: From Biomarkers to Treatment Strategies

Why Some Breast Cancers Stop Responding to Treatment

ESR1 Mutation Testing in Breast Cancer: Setting the Standard for Personalized Oncology?

Unlocking ESR1 Mutations in Breast Cancer

Endocrine Therapies in ER-Positive/HER2-Negative MBC: Understanding Their Benefits and Limitation...

Sherri’s ORSERDU (elacestrant) Story | ESR1 Testing and Disease Progression

ESR1 Mutations: Advancing Precision Therapy in Metastatic Breast Cancer

FDA одобрило препарат Inluriyo: новая надежда для лечения рака молочной железы на поздних стадиях...

FDA одобрило препарат Инлуриё (Имлюнестрант) для лечения рака молочной железы с мутациями ER+, HE...

New Horizons in ESR1-Mutated Breast Cancer

What is Inluriyo? ESR1-Mutated Breast Cancer Treatment

FDA Approves Inluriyo (Imlunestrant) for ESR1-Mutated Breast Cancer - EMBER-3 Insights

Advancing Care in Precision Medicine: Evolving Treatment Strategies in HR+ MBC

Clinical Highlights: Oral SERDs for Patients With HR+/HER2- ESR1-Mutated Advanced Breast Cancer

Biópsia líquida ou tecidual? A escolha certa no ESR1

Breast Cancer Mutations: BRCA1, BRCA2, CHEK2, TP53, ESR1, PIK3CA, MAP3K1 (COMPLETE Guide)

Vepdegestrant could extend PFS for some ESR1-mutated advanced breast cancers